Pfizer's strong Q4/24 results with significant revenue and EPS growth are positive indicators for the stock. The potential in oncology and anti-obesity drugs suggests future growth, which may offset the modest 2025 guidance. However, political challenges and patent expirations pose risks. Overall, the positive earnings report and growth potential are likely to have a favorable short-term impact on Pfizer's stock price.